Subscriber access provided by Universitaetsbibliothek | Johann Christian Senckenberg
Article
Antioxidative nanoparticles significantly enhance therapeutic efficacy of an antibacterial therapy against Listeria monocytogenes infection Yutaka Ikeda, Kazuhiro Shoji, Chitho P. Feliciano, Shinji Saito, and Yukio Nagasaki Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.7b00995 • Publication Date (Web): 18 Feb 2018 Downloaded from http://pubs.acs.org on February 19, 2018
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
Antioxidative
nanoparticles
2
enhance therapeutic efficacy of an antibacterial
3
therapy
4
infection
5
Yutaka Ikeda1, Kazuhiro Shoji1, Chitho P. Feliciano1,2, Shinji Saito3, Yukio Nagasaki1,4
6
1
7
305-8573, Japan
8
2
9
Institute, Department of Science and Technology (PNRI-DOST), Commonwealth
against
Listeria
significantly monocytogenes
Department of Materials Science, University of Tsukuba, Tennoudai 1-1-1, Tsukuba
Biomedical Research Section, Atomic Research Division, Philippine Nuclear Research
10
Avenue, Diliman, Quezon City, Philippines 1101
11
3
12
Japan
13
4
14
Tsukuba, Ibaraki 305-8573, Japan
Faculty of Medicine, University of Tsukuba, Tennoudai 1-1-1, Tsukuba 305-8573,
Master’s School of Medical Sciences, University of Tsukuba, Tennoudai 1-1-1,
15 16
KEYWORDS. Infection, antimicrobial, oxidative stress, antioxidant, nanoparticle
17
Abstract
18
Acute inflammatory conditions such as sepsis lead to fatal conditions,
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
including multiple organ failure. Several treatments such as steroidal anti-inflammatory
2
drugs are currently being investigated in order to decrease the blood cytokine level,
3
which increases remarkably. However, any of these monotherapeutic treatments are not
4
always reliable and effective, and none have drastically improved survival rates, or
5
mostly ended with failure. Reactive oxygen species (ROS) are signaling molecules
6
responsible for the production of cytokines and chemokines that can mediate
7
hyperactivation of the immune response called cytokine storm. In addition to the above
8
mentioned agents, various antioxidants have been explored for the removal of excess
9
ROS during inflammation. However, the development of low-molecular-weight (LMW)
10
antioxidants as therapeutic agents has been hampered by several issues associated with
11
toxicity, poor pharmacokinetics, low bioavailability, and rapid metabolism. In the
12
present study, we aimed to overcome these limitations through the use of antioxidative
13
nanoparticles possessing 2,2,6,6-tetramethylpipelidine-1-oxyl (TEMPO) which are
14
covalently conjugated to polymer. Although treatment with antioxidative nanoparticles
15
alone did not eliminate bacteria, combined treatment with an antibacterial agent was
16
found to significantly improve survival rate of the treated mice as compared to the
17
control group. More importantly, the antioxidative nanoparticles reduced oxidative
18
tissue injury caused by the bacterial infection. Thus, our findings highlighted the
ACS Paragon Plus Environment
Page 2 of 28
Page 3 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
effectiveness of combination treatment with antioxidative nanoparticles and an
2
antibacterial agent to prevent severe inflammation caused by bacterial infection.
3 4
Introduction
5
Despite the development of versatile medical diagnoses, there is still an urgent need for
6
the development of efficient treatments and prevention methods for infectious diseases.
7
Case in point, around 10 million people are predicted to die every year by 2050 because
8
of a continuous rise in drug resistance (1). Pathogenic microorganisms, such as bacteria
9
and viruses, cannot always establish their infection due to the protection by immune
10
systems equipped in host organisms. Reactive oxygen species (ROS) which are
11
produced by phagocytic cells and also by activation of xanthine oxidase (2), (3) are
12
signaling molecules that promote the production of inflammatory cytokines and have
13
been reported to play important roles in immune system (4). For example,
14
myeloperoxidase has been shown to eliminate pathogens by producing hypochlorous
15
acid, which is known as one of ROS (5). NADPH oxidase, which is expressed during
16
inflammation, also kills bacteria by generating ROS (6). D-Amino acid oxidase (DAO)
17
produce hydrogen peroxide from
18
becomes more potent hypochlorite during the antibacterial action (7).
D-amino
acid, and in the presence of (MPO), it
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
However, overamplified defense and inflammatory reactions or over shooting
2
of ROS and/or reactive nitrogen species (RNS) often cause acute responses, such as
3
sepsis and septic shock (8). During these acute responses, inflammatory cells such as
4
neutrophils, macrophages, and lymphocytes produce various pro-inflammatory
5
mediators, such as tumor necrosis factor-α (TNF-α) and interleukins (9). Excessive
6
inflammation also leads to systemic damage, including increased vascular permeability,
7
tissue damage, and overactivation of complement system which causes serious organ
8
failure (10), (11).
9
Overproduction of nitric oxide (NO), which is generated through the activity of
10
inducible nitric oxide synthase (iNOS), has been reported to be associated with
11
decreased vascular tonus and hypotension, which are characteristics of sepsis (12).
12
Overproduction of pro-inflammatory mediators leads to impaired innate immune
13
functions. Given that hyperactivation of the inflammatory response is a feature of sepsis,
14
drug treatments have also targeted these inflammatory mediators in addition to
15
conventional antibiotic treatments. Such treatments include treatment with steroids,
16
antibodies targeting the lipid component of lipopolysaccharide or TNF-α, soluble TNF
17
receptors, and IL-1 receptor antagonists (6).
18
Given the role of ROS in severe inflammation, removal of overproduced ROS
ACS Paragon Plus Environment
Page 4 of 28
Page 5 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
after infection is expected to improve therapeutic efficacy. Many studies have
2
demonstrated the potency of antioxidants for the treatment of sepsis. For example,
3
N-acetylcysteine (NAC), vitamin C, and vitamin E were investigated for their efficacy
4
against sepsis (13). However, the development of these low-molecular-weight (LMW)
5
antioxidants has been hampered because of their poor pharmacokinetics, low
6
bioavailability, and rapid metabolism (14). Another major limitation of LMW
7
antioxidants is their nonspecific internalization by normal cells because of their small
8
sizes, which in turn causes disruption of normal redox reactions such as electron
9
transport chains and consequently leads to redox imbalance (15). Therefore, these LMW
10
antioxidants cannot be administered in high doses to eliminate overproduced ROS.
11
In recent years, we have been developing the antioxidative nanomedicine
12
(radical-containing nanoparticle: RNPs) (16), which can be utilized for the treatment of
13
various ROS-related diseases, such as cancer (17), (18), cerebral (19), (20),
14
cardiovascular (21), and renal ischemia reperfusion injuries (22), Alzheimer’s disease
15
(23), and radiation damage (24). Antioxidative nanoparticles are produced from
16
antioxidative
17
2,2,6,6-tetramethylpipelidine-1-oxyl (TEMPO) as a side chain of the hydrophobic
18
segment (PMOT) and poly(ethylene glycol) (PEG) as the hydrophilic segment (16).
block
copolymers
(PEG-b-PMOT)
ACS Paragon Plus Environment
possessing
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Nanoparticles are produced via self-assembly of PEG-b-PMOTs, and the nitroxide
2
radicals in PEG-b-PMOTs are known to catalytically scavenge ROS. The
3
pharmacokinetics and bioavailability of RNPs are very different from those of LMW
4
antioxidants because of their larger sizes (24). In contrast to conventional LMW
5
antioxidants, RNPs are less likely to be internalized by normal cells and exert minimal
6
side effects (25).
7
In this study, we evaluated the therapeutic effect of RNPs in Listeria
8
monocytogenes (L. monocytogenes)-infected mice. Although treatment with RNP alone
9
did not show significant bacterial killing activity, combined treatment with an antibiotic
10
resulted in enhancement of therapeutic efficacy of an antibacterial therapy (Fig. 1).
11
Figure 1. Schematic illustration of this study
12 13 14
Experimental section
15
Materials
16
Commercial chemicals were used without further purification. Water was
ACS Paragon Plus Environment
Page 6 of 28
Page 7 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
purified using the Milli-Q system (Millipore, Molsheim, France). PEG-b-PMOTs and
2
RNPs
3
hydroxyl-TEMPO
4
copolymers (24) to produce PEG-b-PMOTs (26). RNPs were prepared via dialysis of a
5
DMF solution of PEG-b-PMOT against water.
were
prepared was
according
to
reacted
with
previously
described
methods.
PEG-b-poly(chloromethylstyrene)
Briefly, block
6 7
Animals
8
Animal studies were conducted using seven-week-old male BALB/c mice
9
weighing approximately 20 g. All mice were purchased from Charles River, Japan, Inc.
10
Mice were housed in the experimental animal facilities at the University of Tsukuba,
11
Japan in a temperature- and humidity controlled-environment with a 12-h light/12-h
12
dark cycle. All mice were fed commercial chow and sterilized water ad libitum. All
13
experiments were performed according to the Guide for the Care and Use of Laboratory
14
Animals of the University of Tsukuba (Animal Plan Number: 16-323).
15 16
Treatment of L. monocytogenes-infected mice
17
Pure cultures of Listeria monocytogenes (ATCC13932) was routine cultured in
18
tryptic soy broth (TSB) and cultured at 37 °C for 24 h. The bacterial suspension in
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
saline was adjusted to a final concentration of 1×1012 CFU/mL prior to its use. The
2
number of bacteria was measured by Mcfarland standards. The L. monocytogenes
3
solution (200 µL) was intraperitoneally injected into BALB/c mice (27). RNP,
4
amoxicillin and/or hydroxyl-TEMPO were intraperitoneally injected according to the
5
schedule described in the Figure. Numbers of mice of each treatment group were
6
described in the Figure legends. At least four mice were used for the treatment.
7 8
Evaluation of bacteria counts in organs
9
Mice organs (liver, spleen, lungs and blood) were collected after 0, 1, and 2
10
days after injection with L. monocytogenes and immersed in 0.9% NaCl solution at the
11
final concentration of 0.1 g/mL. Sample organs were homogenized, serially diluted with
12
saline, and plated on tryptic soy agar plate for bacterial enumeration following the
13
standard plate count procedure (28). Plated samples were incubated at 37 °C for 24 h.
14
After incubation, colony forming units were manually counted and the corresponding
15
CFU per gram was calculated.
16 17 18
TBARS assay Mice organs (100 mg) were homogenized by the ultrasonic homogenizer in 1
ACS Paragon Plus Environment
Page 8 of 28
Page 9 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
mL of 1.15% KCl solution. Then, 200 µL of the homogenized solution was mixed with
2
20% trichloroacetic acid solution (50 µL) and 1% thiobarbituric acid (50 µL) solution,
3
followed by heating at 37 °C for 30 min. After cooling, 250 µL of an n-butanol:pyridine
4
(15:1 v/v) mixture was added to the samples, and the mixture was vortexed thoroughly
5
(29). After centrifugation at 1470×g for 10 min, the organic layer was removed, and
6
fluorescence (532 nm) was measured on a Varioskan Flash (Thermo Scientific). The
7
concentration of malondialdehyde (MDA) which is produced from lipid peroxides and
8
reacts with thiobarbituric acid (TBA) to form MDA-TBA adduct was determined by
9
measuring fluorescence at 532 nm using tetramethoxypropane as an external standard.
10 11
Statistical analysis
12
In all experiments, statistical analyses were performed using one-way analysis of
13
variance, followed by Tukey’s post hoc test. A value of p < 0.05 was considered
14
significant for all statistical analysis.
15
Results
16
Generation of L. monocytogenes-infected model mice
17
In this study, bacterial infection model mice were prepared by intraperitoneal
18
injection of L. monocytogenes into BALB/c mice. Infection dose was determined at
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
2×1011 CFU because high mortality rate of mice and organ failures were observed at
2
this dose. Bacterial counts rapidly increased at 1 day after injection, and mice began to
3
die at 2 days after injection. Considering the rapid bacterial growth, we decided to
4
administer the treatment immediately after the bacterial injection and subsequently,
5
begin the evaluation.
6
In this study, amoxicillin was chosen as antibacterial agent against L.
7
monocytogenes because amoxicillin is one of penicillin which is used for the treatment
8
of L. monocytogenes infection. MIC value of amoxicillin determined by a dilution
9
method was 1.0 µg/mL. The model mice were administered with varying doses of
10
amoxicillin (i.p.) to determine the suitable dose. All infected mice survived by the
11
treatment with amoxicillin at doses higher than 25 mg/kg. By contrast, infected mice
12
treated with amoxicillin at 15 mg/kg showed significantly reduced survival rates,
13
although better than no drug control, indicating that the antibacterial efficacy was not
14
sufficient at this dosage (Fig. 2). Therefore, mice were administered amoxicillin (i.p.) at
15
15 mg/kg in subsequent experiments. Administration of RNPs alone did not exert any
16
therapeutic effect in infected mice even at a high dose (200 mg/kg) (data not shown).
17
This is consistent with our previous in vivo findings, which showed that RNPs did not
18
directly affect the bacteria in the coronal mucosa (26). Thus, treatment with
ACS Paragon Plus Environment
Page 10 of 28
Page 11 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
antioxidative nanoparticles alone is not directly effective against L. monocytogenes
2
infection. Based on these results, we next investigated whether the therapeutic efficacy
3
of amoxicillin at 15 mg/kg will be improved when injected in combination with RNPs.
4 5
Figure 2. Survival rates of L. monocytogenes-infected mice at different doses of amoxicillin.
6
Circle: amoxicillin at 25 mg/kg; square: amoxicillin at 15 mg/kg; triangle: saline solution (n=4).
7 8
Treatment of L. monocytogenes-infected mice
9
As mentioned above, RNPs alone did not exert any therapeutic effect in the infected
10
mice. Thus, we investigated the therapeutic effect of amoxicillin in combination with
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
RNPs. Figure 3 shows the procedure for the combination treatment. RNPs (200 mg/kg)
2
were intraperitoneally injected twice (on the same day and one day after injection with L.
3
monocytogenes). Amoxicillin (15 mg/kg) was also intraperitoneally injected daily for
4
five days. Although treatment with amoxicillin alone showed therapeutic effect, all mice
5
died after 6 days. By contrast, three out of the five mice subjected to combination
6
treatment survived for more than 6 days, demonstrating the improved therapeutic effect
7
of the combination therapy. This result clearly indicates prolonged antioxidative activity
8
of RNPs (24) protected mice from the serious damages caused by infection.
9
Bacterial counts in the blood, liver, and spleen were also determined (Fig. 4).
10
Bacterial counts in infected mice without any treatment continuously increased with
11
time. By contrast, bacterial numbers were significantly lower in mice treated with either
12
amoxicillin alone or in combination with RNPs two days after infection, thereby
13
confirming the antibacterial effect of amoxicillin. Notably, there were no significant
14
differences in bacterial counts between the mice injected with and without RNPs,
15
further validating that the RNPs did not exert bacteria-killing activity.
16
ACS Paragon Plus Environment
Page 12 of 28
Page 13 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1 2
3 4
Figure 3. Combination therapy of L. monocytogenes-infected mice. a) Treatment
5
procedure. b) Survival rates of infected mice. Diamond: uninfected mice; triangle:
6
infected mice treated with amoxicillin and RNPs; circle: infected mice without
7
treatment; square: infected mice treated with amoxicillin alone (n=5).
8
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2
Figure 4. Bacterial counts in organs. a) blood; b) liver; c) spleen; d) lungs. Circle:
3
Infected mice without treatment; triangle: infected mice treated with amoxicillin and
4
RNPs; square: infected mice treated with amoxicillin alone. Accuracy was assessed by
5
conducting replicate analysis (n = 4).
6 7
Protection of organs from oxidative damage
8
Oxidative tissue damage is a typical feature of bacterial infection (12).
9
Progression of oxidative damage in multiple organs can be observed during sepsis.
10
Accordingly, protection of organs from oxidative damage is a promising strategy for the
11
treatment of infections. To investigate the extent of oxidative damage during infection,
ACS Paragon Plus Environment
Page 14 of 28
Page 15 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
levels of malondialdehyde (MDA), a typical byproduct of lipid peroxidation, were
2
measured in the liver, lungs, and spleen via TBARS assay. Mice were sacrificed at 1 day
3
after injection with L. monocytogenes. A significant increase in MDA levels after
4
infection was confirmed, demonstrating the role of oxidative mechanisms in bacterial
5
infection-induced tissue damage. Importantly, MDA levels in organs were lower in L.
6
monocytogenes-infected
7
nanoparticles (RNPs, 200 mg/kg). As shown in Fig. 5, MDA levels in all organs
8
investigated in this study (liver, lungs, and spleen) were significantly lower in infected
9
mice treated with RNPs than in untreated mice. These results clearly suggested that the
10
antioxidative nanoparticles exerted a protective effect against oxidative damage caused
11
by bacterial infection, although treatment with RNPs alone did not directly kill the
12
bacteria.
mice
intraperitoneally
administered
with antioxidative
13
14 15
Figure 5. MDA levels in various organs. a) Liver; b) lungs; c) spleen. Accuracy was
ACS Paragon Plus Environment
Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Page 16 of 28
assessed by conducting replicate analysis (n = 4). *P